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Mixing Time Effects on the Dispersion Performance of
Adhesive Mixtures for Inhalation
Floris Grasmeijer*, Paul Hagedoorn, Henderik W. Frijlink, H. Anne de Boer
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
Abstract
This paper deals with the effects of mixing time on the homogeneity and dispersion performance of adhesive
mixtures for inhalation. Interactions between these effects and the carrier size fraction, the type of drug and the
inhalation flow rate were studied. Furthermore, it was examined whether or not changes in the dispersion
performance as a result of prolonged mixing can be explained with a balance of three processes that occur during
mixing, knowing drug redistribution over the lactose carrier; (de-) agglomeration of the drug (and fine lactose)
particles; and compression of the drug particles onto the carrier surface. For this purpose, mixtures containing
salmeterol xinafoate or fluticasone propionate were mixed for different periods of time with a fine or coarse crystalline
lactose carrier in a Turbula mixer. Drug detachment experiments were performed using a classifier based inhaler at
different flow rates. Scanning electron microscopy and laser diffraction techniques were used to measure drug
distribution and agglomeration, whereas changes in the apparent solubility were measured as a means to monitor the
degree of mechanical stress imparted on the drug particles. No clear trend between mixing time and content
uniformity was observed. Quantitative and qualitative interactions between the effect of mixing time on drug
detachment and the type of drug, the carrier size fraction and the flow rate were measured, which could be explained
with the three processes mentioned. Generally, prolonged mixing caused drug detachment to decrease, with the
strongest decline occurring in the first 120 minutes of mixing. For the most cohesive drug (salmeterol) and the coarse
carrier, agglomerate formation seemed to dominate the overall effect of mixing time at a low inhalation flow rate,
causing drug detachment to increase with prolonged mixing. The optimal mixing time will thus depend on the
formulation purpose and the choice for other, interacting variables.
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Introduction
Lacey was one of the first to describe the mixing process as
the creation of disorder by allowing chance to determine the
positions of the particles. With increased mixing time these
chance effects accumulate, eventually resulting in a more or
less stable equilibrium of maximum disorder [1]. The theoretical
‘random’ mixing process addressed by Lacey excludes particle
interaction phenomena and is therefore fundamentally different
from the ‘ordered’, or rather, ‘total’ mixing process that best
describes the formation of adhesive mixtures for inhalation
[2–4]. In both instances the role of mixing time is essentially the
same, however, in that it allows chance effects to accumulate
and therefore determines the extent to which certain processes
within the mixture take place.
On blending of adhesive mixtures for inhalation several such
processes can be distinguished. For example, it has been
shown that drug agglomerates which are present in the starting
material will be broken up [5,6] and evidence suggests that at
the same time new, less coherent agglomerates can be formed
[7]. Furthermore, the inhomogeneous nature of lactose carrier
surfaces allows for redistribution of drug particles to occur
between surface sites with a different binding activity or sites
with a different capacity to offer sheltering to drug particles
from the redistribution forces during further mixing [2,4,8,9]. In
addition, repeated press-on forces and possibly
triboelectrification effects may gradually increase interaction
forces between drug and carrier particles [10–12]. Lactose
fines might also be generated by attrition of the carrier, but this
process seems to be restricted to high shear blending
operations [13,14].
The three processes that are expected to principally affect
the dispersion performance of adhesive mixtures and that are
therefore subject of this study can be summarised as
agglomeration, distribution and press-on processes,
respectively. They each may alter the dispersion performance
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of the mixture in a different direction and with a different
magnitude. Therefore, it is to be expected that the overall effect
of mixing time on the dispersion behaviour of any carrier-based
inhalation formulation is primarily related to the obtained
balance between these three principal processes. This also
implies that any variable that alters this balance may interact
with the effect of mixing time.
The carrier size fraction, the drug concentration and the flow
rate were previously identified as variables that can interact
with the effect of mixing time on drug detachment during
inhalation [15,16]. These variables either directly affect the
different processes during mixing by influencing the potential
and propensity for drug redistribution and (de-) agglomeration
or the magnitude and efficacy of press-on forces, or they affect
the significance of their occurrence in relation to drug
detachment by altering the dispersion efficacy. For example,
the agglomeration behaviour of drugs in adhesive mixtures was
shown to be proportional to the carrier size fraction, or more
specifically, the interparticulate pore size of the carrier powder
bed [7,17]. Furthermore, the significance of a change in drug
particle mass (agglomerate size) in relation to drug detachment
from lactose carriers during inhalation was found to decrease
with increasing dispersion efficacy (e.g. with higher flow rates
through the inhaler) [18]. Therefore, for a given drug-carrier
combination agglomerate formation is most likely to be a
dominant process determining the effect of mixing time on drug
detachment when coarse carrier particles are used and
dispersion tests are performed at a low flow rate. Another
variable that may change the balance of the different
processes during mixing and could therefore interact with the
effect of mixing time is the type of drug: the balance of intrinsic
cohesive to adhesive interaction energy in combination with
lactose can be different between drugs, and therefore, so may
be their propensity towards agglomeration [19].
Mixing is unquestionably the most important unit operation in
the formulation of adhesive mixtures for inhalation and mixing
time is an easily controllable process parameter. Despite this,
the effect of mixing time on formulation performance and its
relation to all the other variables to be considered is still not
fully understood for carrier-based inhalation formulations. As a
start to straightening out this discrepancy this paper deals with
the effect of mixing time on drug detachment for adhesive
mixtures with a relatively low drug content. In particular
interactions between mixing time and the type of drug, the
carrier size fraction and the flow rate are investigated. Starting
point of this study is the idea that the balance of mainly drug
(de-) agglomeration, redistribution over and compression onto
the carrier surface determines the overall effect of mixing time
on drug detachment. Therefore, different characterisation
techniques have been used in an attempt to measure or
monitor the occurrence of these three ‘principal processes’




Alpha lactose monohydrate (Pharmatose 80M, DMV-
Fonterra Excipients, Goch, Germany) was used to prepare the
different carrier size fractions. Micronised salmeterol xinafoate
and fluticasone propionate were granted by Novartis
(Germany). These drugs were chosen for their difference in
cohesion-adhesion balance in combination with lactose, which
was previously reported to be 2.39 and 0.22, respectively [20].
The drugs were passed through a 90 µm sieve to break up
larger agglomerates and triboelectric charge resulting from the
screening process was allowed to decay for at least 2 days
afterwards.
X-ray diffraction
The change in characteristics of drug particles when
subjected to mechanical stress during mixing may depend on
their initial solid state. For example, disordering or
amorphisation of initially crystalline particles results in a higher
apparent solubility [21,22]. Therefore, the solid state of the
drugs as used was measured by X-ray diffraction with a D2
PHASER equipped with a 1 mm divergence slit and a
LYNXEYETM detector (Bruker AXS B.V., Delft, The
Netherlands). Approximately 15 mg of the micronised material
was evenly spread on a zero background Si sample holder
without the use of an adhesive. The sample holder was rotated
at 60 rpm during measurement and it was made sure that the
powder was still in place afterwards. An air-scatter screen of 1
mm was used to prevent radiation from the X-ray source to
directly reach the detector. The scans were performed from 5
to 40 ° 2θ with a step size of 0.01 ° 2θ and a 1 s step duration.
CuKα radiation with a wavelength of 1.5406 Å was generated
at 30 kV and 10 mA. The measurements were performed on at
least two different specimens from the same powder sample to
ascertain the reproducibility of the obtained diffraction pattern.
Carrier classification
A coarse (250-315 µm) and a fine (63-90 µm) carrier fraction
were obtained from Pharmatose 80M by 20 minutes of
vibratory sieving at an amplitude of 1.5 mm (Retsch AS 200
control, Germany). To further remove lactose fines from the
surface of the carrier particles, the carrier fractions were then
air jet sieved for 10 minutes (e200LS, Hosokawa Alpine AG,
Augsburg, Germany); the coarse fraction on a 250 µm sieve at
an underpressure of 2000 Pa and the fine fraction on a 63µm
sieve at 3000 Pa.
Blend preparation
Blends were prepared at ambient conditions. The coarse
carrier fraction was blended with 0.4% of drug and the fine
carrier with 1.48% to obtain a similar carrier surface payload (in
mg/m2, calculated based on the ratio of the arithmetic mean
fraction diameters). The drug was sandwiched in between two
equal parts of the carrier material in a stainless steel mixing
vessel with a volume of 160 cm3 and pre-mixed with a spatula
for approximately 20 orbits. The blends were subsequently
mixed with a Turbula blender operated at 90 rpm (WA
Bachofen, Basel, Switzerland) for 0.5 to 780 minutes. Data for
different mixing times are obtained from the same batch,
starting with a batch size of 25 g which decreased to
approximately 15 g for the final blending step due to the
extraction of samples. For both carrier fractions placebo blends
Mixing Time Effects on Powders for Inhalation
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(containing only the carrier material) were prepared in the
same way.
Content uniformity testing
Content uniformity of the blends was tested by taking 10
samples of 25 ± 1 mg from random positions. Blend
homogeneity was considered acceptable at relative standard
deviations (RSDs) of the content < 3%. The mean value of the
10 samples was taken as the drug content in the mixture.
Segregation sensitivity testing
To confirm a possible explanation for the content uniformity
data, the segregation sensitivity of the salmeterol mixtures
containing a coarse carrier and being mixed for 2 and 420
minutes was tested. To this end, 1 g samples were subjected
to the described vibratory sieving procedure during 1 minute on
a 150 µm test sieve. The salmeterol content of the sieving
residue was determined from 5 samples of 25 ± 1 mg and
expressed relative to the salmeterol content of the original
blends.
Scanning electron microscopy (SEM)
The (re-)distribution and agglomeration behaviour of the drug
on the carrier with mixing time was studied with SEM. Images
were obtained with a JSM-6301F (Jeol, Japan) at an
acceleration voltage of 3kV and probe current 7. Samples were
fixed on an aluminium specimen mount by means of double
sided adhesive carbon tape. For the pure drugs excess sample
was blown from the tape with pressurised air. Any excess
particles from the carrier material and blends were gently
tapped from the specimen mount to avoid detachment of
lactose fines or drug from the carrier crystals, respectively. The
drugs were sputter coated with 10 nm of a gold–palladium
alloy, whereas for the carrier and mixture samples a coating
thickness of 20 nm was found to be necessary for preventing
charging effects.
Laser diffraction analysis
All laser diffraction experiments have been performed with
the HELOS BF diffractometer (Sympatec, Clausthal-Zellerfeld,
Germany) equipped with an R3 lens (measuring range 0.9-175
µm) or an R5 lens (measuring range 4.5-875 µm, for the
coarse carrier fraction). The FREE calculation mode was used,
which is based on the Fraunhofer theory.
Dry dispersion.  The particle size distributions (PSDs) of the
drugs were measured after dispersion of the powders with a
RODOS disperser at 3 bar (Sympatec, Clausthal-Zellerfeld,
Germany). The PSDs did not change when the pressure drop
for dispersion was increased to 5 bar, which indicates that the
primary PSDs of the drugs were measured. Results are the
mean of 2 measurements, which was deemed a sufficient
number of replicates with the added control measurements at a
dispersion pressure of 5 bar and considering the small
deviations that were observed between individual
measurements.
The PSDs of both lactose carrier fractions were measured in
the same way at 3 and 5 bar. Approximately 2 g of the sieved
and placebo blended material was fed to the RODOS disperser
through a funnel. Results are the mean of 3 measurements.
Wet dispersion.  To further quantify the qualitative
information from SEM, the agglomeration behaviour of the
drugs on the carrier with prolonged mixing was measured with
laser diffraction too. The agglomerate size of the hydrophobic
drugs as present in the screened starting material and in the
blends was measured in aqueous suspensions using the
CUVETTE SC-40 module (50 mL cuvette, Sympatec,
Clausthal-Zellerfeld, Germany). A sample of the blend was
added to saturated aqueous solutions of the drugs containing
approximately 0.03% of polysorbate 80 (Tween 80). The
particle size distributions of suspended drug agglomerates
were measured for 10 s after precisely 12 minutes (coarse
carrier) or 2 minutes (fine carrier); the duration in which the
lactose completely dissolved for all samples. Dissolution of the
lactose carrier was apparent from a disappearing peak
corresponding to the size of the carrier material and further
confirmed by optical microscopy of the suspensions (see
further). A stirring speed of approximately 500 rpm was used
throughout the entire procedure to prevent sedimentation of the
suspended drug particles. It was made sure that the
hydrophobic drugs did not adhere to the wall of the cuvette
during measurement. Sample sizes were chosen such that an
optical concentration of around 10% was obtained. It was
checked that dissolved lactose did not influence the laser
diffraction results. The primary PSDs of the drugs were
measured after wet dispersion in a similar way after a pre-
suspension step comprising sonication of approximately 0.5 mg
of the drugs in 2 mL of the saturated solution for 11 minutes
using a 70 W, 42 kHz ultrasonic cleaner (Electris UC449UP,
France). The amount of pre-suspension that was added to the
CUVETTE was titrated to an optical concentration of around
10%. It was checked that the optical concentration and
characteristic PSD data of the primary particles thus measured
remained constant for minimally 12 minutes. The chosen
conditions and procedures are the result of their careful
evaluation concerning reliability and reproducibility during many
exploratory measurements. Results are the mean of at least 3
measurements.
Optical microscopy
Aqueous suspensions of the adhesive mixtures were
inspected by optical microscopy to confirm the dissolution of
the lactose carrier (BX50F, Olympus Optical Co., Ltd., Japan).
Several drops of the suspensions were placed on a glass
microscope slide without using a cover slip.
Solubility testing
The apparent solubility of salmeterol was measured as a
means to quantify the degree of mechanical stress imparted on
the drug particles during the mixing process. An aqueous
suspension of salmeterol was prepared by suspending the
micronised starting material in demineralised water containing
approximately 0.03% polysorbate 80 (Tween 80). After
sonication for at least 30 minutes in a Helma Transsonic 700/H
ultrasonic bath (Elma Hans Schmidbauer, Singen, Germany)
the suspension was stored in the dark for 1 week without
Mixing Time Effects on Powders for Inhalation
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stirring before further use. Thereafter, the suspension was
passed through a 0.2 µm cellulose acetate filter to obtain a
saturated solution. The apparent solubility strongly depends on
the suspended drug concentration [21,22]. Therefore, to 10 mL
of the saturated solution, 0.7 mg of the salmeterol starting
material was added or a sample of the different salmeterol
mixtures that resulted in an equivalent added salmeterol mass
(calculated based on the measured content). The resulting
suspensions were regularly vortexed during 1 hour. Exploratory
measurements showed that, for the longest mixing times,
maximum dissolution is attained within 1 hour and that the
concentration consecutively decreases towards the equilibrium
saturation concentration in the course of several days to
weeks. The procedure was continued by passing the
suspensions through a 0.2 µm cellulose acetate filter. The
samples were further analysed as discussed in the section
‘spectrophotometric analysis’. Results are the mean of 2
measurements.
Drug detachment experiments
Drug detachment was measured by analysing the residual
amount of drug present on the carrier surface after a dispersion
experiment with a classifier based test inhaler [23]. The carrier
crystals could be collected for analysis after a drug detachment
experiment, since they were retained in the classifier of the
inhaler. The residual amount of drug normalised to 100% of the
carrier is referred to as ‘carrier residue’ (CR). The percentage
of drug detached is calculated as 100-CR. Doses of 25 ± 1 mg
were used for the drug detachment experiments, which were
performed at flow rates of 20 and 60 L/min for a fixed duration
of 3 seconds. Drug detachment experiments for the same flow
rate and drug-carrier combination (at different mixing times)
were performed on the same day to minimise environmental
effects. Results are the mean of 5 measurements.
Spectrophotometric analysis
Samples from the content uniformity analyses and drug
detachment experiments were analysed for salmeterol and
fluticasone content by spectrophotometric analysis at a
wavelength of 228 nm (Unicam UV-500, ThermoSpectronic,
Cambridge, UK). Calibration curves for the concentration of
both drugs were constructed with a coefficient of determination
of 0.9998. All samples were dissolved in ethanol and
subsequently centrifuged for 5 minutes at 3000 rpm (Hettich
Rotanta D-7200, Hettich AG, Switzerland) to clear the drug
solutions from suspended lactose particles prior to
measurement. If necessary, samples were diluted for the drug
concentrations to fall within the range covered by the
calibration curves.
The absorbance of the samples from the solubility tests was
measured spectrofotometrically at a wavelength of 280 nm.
The measurement at this wavelength avoids the necessity of
dilution of the supersaturated salmeterol solutions in order for
the absorption values to fall within the linear measuring range
of the spectrophotometer used. Water containing 0.03% of
polysorbate 80 and the dissolved pure lactose carrier (if
applicable) was used as a blank. Because only the relative
difference in the apparent solubility of salmeterol between the
different samples is of interest, an exact quantification of the
salmeterol concentration is not necessary and no calibration
curve was constructed.
Results and Discussion
Solid state of the drugs
The X-ray diffraction patterns of the drugs are presented in
Figure 1. Judging from the sharp peaks and the lack of a ‘halo’
both drugs are crystalline.
Particle size distributions of the drugs and carrier
materials
Because the volume median diameters of the drugs are well
within the desirable size range for inhalation of 1-3 µm (see
Table 1), the drugs are considered suitable for use in these
experiments.
The carrier material as obtained after the classification
procedure still contained a measurable amount of fines, which
is presented in Table 1 as the volume fraction < 10 µm.
Placebo mixing of both carrier fractions unexpectedly resulted
in a trend of decreasing volume fraction < 10 µm. The loss of
fines with mixing was confirmed by visual observation of the
carrier particles with SEM (Figure 2). The reduction of the
amount of fines may be explained by their adhesion to the
inner walls of the mixing vessel, which resulted in a faint white
haze being visible after placebo mixing.
The data from RODOS dispersion suggest that the fine
carrier fraction contains a higher volume fraction of lactose
fines than the coarse carrier fraction. However, because the
specific surface area of the fine carrier fraction is approximately
3.7 times that of the coarse carrier (calculated based on the
ratio of the arithmetic mean fraction diameters), their fines
content per unit carrier surface area may well be comparable.
This statement is supported by Figure 2, in which both carrier
fractions are shown at a different magnification so as to display
the carrier particles at the approximate same size. There is no
notable difference in surface coverage by fines between the
fine and coarse carrier fractions. Differences in the size
distribution of the lactose fines may exist between the carrier
fractions, however.
The appearance of lactose fines in commercial carrier
products is inevitable as they cannot be effectively removed.
They will influence the balance of the principal processes (i.e.
drug (de-) agglomeration, redistribution and compression)
during mixing of the blends to certain extent. Based on the
placebo experiments it may be expected that in our study drug
detachment will not be affected by mixing time through the
generation of new lactose fines. Furthermore, any difference in
the effect of mixing time on drug detachment between both
carrier fractions is not likely to be the result of a difference in
the covering of the carrier by lactose fines. However, it is not
clear to what extent this may be determined by other factors
too, such as differences in the scale of carrier surface
discontinuities between the carrier fractions.
Content uniformity
A trend of decreasing drug content with prolonged mixing
was observed for both drugs mixed with the coarse carrier
Mixing Time Effects on Powders for Inhalation
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(Table 2, 0.4% of drug). This is the result of drug adhesion to
the inside of the mixing vessel, which was observed as the
formation of a white haze that became more opaque as mixing
was continued. For the fine carrier, drug losses occurred
mostly at the early onset of mixing after which the content
stayed relatively constant (Table 2, 1.48% of drug). The
difference in absolute drug loss to the mixing vessel wall
between the carrier fractions is small (approximately 15 and
18.5 mg for the coarse and fine carrier fraction, respectively),
which suggests that the drug loss is largely determined by
saturation of the mixing vessel’s inner walls, which is
independent of the carrier type. The losses are of the same
order of magnitude for both drugs.
For all blends the RSD of the content is < 3% and they are
therefore considered homogeneous (Table 2). No meaningful
change in RSD with increased mixing time is observed, only
the RSD of the 0.4% salmeterol mixture after 420 minutes of
mixing is notably higher. This higher RSD accompanies an
increase in segregation sensitivity. Between 2 and 420 minutes
of mixing the drug loss resulting from 1 minute of vibratory
sieving increases from 15.6% to 52.4%.
Agglomeration effects
Scanning electron microscopy.  The relatively lower
degree of homogeneity and increased segregation sensitivity
for the 420 min 0.4% salmeterol mixture are likely the result of
a high degree of agglomeration of the salmeterol (and possibly
fine lactose) particles onto or in between the coarse carrier
particles. For the large agglomerates of approximately 25 µm
that are visible in Figure 3 (C1 and C2) gravitational forces start
to dominate adhesion forces. This shifts the balance between
randomisation and ‘ordering’ or adhesion in favour of
randomisation [4]. The reproducibility of the formation of large
agglomerates was confirmed by SEM for at least three different
batches of 0.4% salmeterol prepared. A less pronounced
agglomeration of salmeterol with prolonged mixing is observed
on the fine carrier (Figure 4). The agglomerates are less
numerous and they are smaller than those on the coarse
carrier (no larger agglomerates than about 10 µm could be
found in the specimen). This observation suggests that
agglomeration may occur in the carrier surface irregularities,
which are larger for the coarse carrier. These data are in line
with the conclusion from previous studies that the size of drug
Table 1. Characteristic PSD data (average (SD)) of the
drugs (n = 2) and carrier material (n = 3).
 X50 (µm) V% < 10 µm
Salmeterol (dry) 1.41 (0.01) 99.99 (0.01)
Salmeterol (wet) 1.43 (0.01) 100
Fluticasone (dry) 1.80 (0.06) 99.85 (0.03)
Fluticasone (wet) 1.59 (0.02) 99.53 (0.04)
Fine carrier 72.04 (0.28) 1.65 (0.06)
Fine placebo* 74.75 (0.60) 1.15 (0.51)
Coarse carrier 289.97 (4.29) 0.34 (0.41)
Coarse placebo* 288.69 (0.87) 0.15 (0.01)
* The fine and coarse carrier as obtained after the sieving procedure have been
placebo blended for 600 and 420 minutes, respectively.
Figure 1.  X-ray diffraction data for salmeterol xinafoate (SX) and fluticasone propionate (FP).  
doi: 10.1371/journal.pone.0069263.g001
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agglomerates after mixing increases with increasing carrier
particle size [7,17]. However, the conclusions from those
studies are based on mixtures containing equal drug contents.
This results in a higher carrier surface payload (mg/m2) for
larger carrier size fractions, which may also cause an increase
in agglomerate size. In our study a difference in carrier surface
payload cannot have caused the difference in agglomeration
behaviour between both carrier size fractions, as it was kept
constant.
The agglomeration behaviour of fluticasone is markedly
different from that of salmeterol when mixed with the coarse
carrier depending on the mixing time. Some fluticasone
agglomerates could be found in the specimen after 420
minutes of mixing (Figure 5, C1 and C2), but they are smaller
(maximally about 10 µm) and less numerous than is the case
for salmeterol (Figure 3, C1 and C2). When mixed with the fine
carrier, the difference in agglomeration behaviour between
fluticasone (Figure 6) and salmeterol (Figure 4) is not as
pronounced. Evaluations based on SEM images can lead to
biased or incorrect conclusions, however. Disadvantages
inherently associated with SEM imaging include the difficulty of
representative sampling from the mixture, representative
imaging of a specimen and the possible altering of the sample
during its preparation. SEM images presented in this paper are
therefore images that have been obtained with utmost care to
ascertain their representativeness. Their selection has been
made after studying multiple samples and batches and imaging
different spots of the same specimen. In addition, care was
taken for the gentle handling of the powder during sample
preparation. Nevertheless, one should keep in mind that
conclusions from SEM imaging are based on a very limited
number of observations, which is why laser diffraction was
used in this study as an additional characterisation technique.
The difference in the propensity towards agglomeration
between both drugs, which becomes especially notable after
prolonged mixing with the coarse carrier, can be explained by a
difference in their balance of intrinsic cohesive to adhesive
interaction energy in combination with lactose. Values for the
cohesion-adhesion balance (CAB) of salmeterol and
fluticasone with lactose have previously been reported to be
Figure 2.  Representative SEM images of the sieved and placebo blended carrier material.  Mixing times for the placebo
blends displayed are 420 and 600 minutes for the coarse and fine fraction, respectively.
doi: 10.1371/journal.pone.0069263.g002
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2.39 and 0.22, respectively [20]. This means that the
cohesiveness of salmeterol is 2.39 times its adhesiveness to
lactose, whereas for fluticasone the adhesiveness to lactose is
4.55 times its cohesiveness. Although these results have been
obtained with different batches of material (which may
influence CAB values significantly [24]), they are in agreement
with the greater agglomeration tendency of salmeterol than that
of fluticasone observed in this study.
Laser diffraction analysis.  The wet suspension laser
diffraction method provides data on the agglomeration
behaviour of salmeterol that are in agreement with the
observations from SEM (Figure 7). The X50 of 93 µm at t = 0
min represents the agglomerate size of the screened starting
material. These agglomerates are quickly dispersed during
blending with the coarse carrier until a minimum X50 of only
2.71 µm is reached after 10 minutes, which approaches the
primary particle size of the drug (Table 1). Continued mixing
then results in a gradual increase of the X50 to a value of 25.4
µm after 420 minutes. As discussed, agglomerates of the same
order of magnitude have been observed with SEM (Figure 3,
C1 and C2). For the fine carrier fraction, a minimum in X50 is
reached after 120 minutes, which remains very much the same
(around 5 µm) during continued mixing. Compared to the X50-
value of the primary salmeterol particles (Table 1) this confirms
the occurrence of only minor agglomeration, as was concluded
from SEM micrographs too.
Although these data for salmeterol may be in agreement with
the images from SEM, they are likely to be biased by
dissolution effects and subsequent deagglomeration in
suspension. It was noticed that with prolonged mixing a larger
sample of the blends was required to attain the desired optical
concentration of around 10% (up to a 6-fold difference between
the shortest and longest mixing times for both carrier fractions).
This observation can neither be explained by the slightly lower
drug content with prolonged mixing (Table 2), nor by
differences in the particle size distribution of the agglomerates
(especially for the fine carrier). It is much more likely the result
of an increasing apparent solubility of salmeterol with increased
mixing time that causes improved dissolution of the drug and
thus the formation of a supersaturated solution (Figure 8).
Therefore, the conclusion has to be drawn that the salmeterol
data in Figure 7 may to certain extent be biased by dissolution
effects, especially for long mixing times. This may result in
enhanced dispersion of agglomerates, and thus
underestimation of the agglomerate size.
For fluticasone, laser diffraction data are not in agreement
with the SEM images (Figure 7). With the coarse carrier, a
maximum agglomerate size in the mixture of 25 µm is
measured after 60 minutes of mixing, but agglomerates of this
size could not be observed in the mixture by SEM (Figure 5, B1
and B2). For the fine carrier the difference is even more
pronounced with a maximum of 75 µm after 780 minutes of
mixing determined by laser diffraction measurements, whereas
only small agglomerates of maximally 4-10 µm could be found
with SEM (Figure 6, D1 + D2). The value of 75 µm coincides
remarkably well with the size of the carrier particles. Light
microscopic imaging of the suspensions revealed that this
discrepancy is the result of the formation of insoluble, thin films
that consist of the drug material and have sufficient structural
integrity to remain intact in suspension after complete
dissolution of the carrier. For the fine carrier these films have
shapes similar to those of the carrier particles (Figure 9, top),
whereas for the coarse carrier the films cover a relatively
smaller part of the particle surface (Figure 9, bottom). Possibly
the larger surface irregularities prevent the formation of a
continuous film over the complete surface of the coarse carrier.
Spontaneous re-agglomeration of drug particles after
suspension is a well-known possible source of bias with wet
laser diffraction measurements too. However, such a process
is not likely to have contributed to the discrepancy between
results from laser diffraction and SEM for fluticasone: no
increase in the X10, X50 or X90 values was observed for any of
the mixture samples during or after dissolution of the carrier
material or for the suspended primary particles.
The formation of a film or coating on the carrier surface by
both drugs can be observed with SEM too, especially on the
fine carrier (Figures 4 and 6, D2). For salmeterol, film formation
on the fine carrier could also be confirmed by suspension of the
blend mixed for 600 minutes in a supersaturated drug solution.
Then, similar films as shown in Figure 9 (top) for fluticasone
were observed by light microscopic imaging several minutes
after submersion of the particles (images not shown). This
confirms that dissolution and dispersion prior to the laser
diffraction measurements (Figure 7) must have occurred for
salmeterol. The apparent solubility of fluticasone in the medium
used in this study is too low to be reliably measured by
spectroscopy, even after prolonged mixing. This explains why
dissolution effects did not occur for fluticasone and the films
remained intact in the suspension medium during the laser
diffraction measurements.
Dissolving the carrier material to allow the measurement of
drug agglomerates in suspension is a commonly applied
technique [5,6,17]. However, such data are a measure of the
strength of agglomerates as well as their size, because de-
agglomeration can occur during the time required for
dissolution of the carrier. This will be more pronounced for
weaker agglomerates. In addition, fines of the same material as
Table 2. Content uniformity test results for blends
containing 0.4% drug on a coarse lactose carrier or 1.48%
drug on a fine lactose carrier (n = 10).




time Content*RSD (%)Content*RSD (%)Content*RSD (%)Content*
RSD
(%)
0.5 min 95.3 0.91 97.4 1 95.5 0.96 96.5 1.23
2 min 94.9 0.89 97.1 0.8 96.5 0.75 95 1.47
10 min 93.5 0.61 94 0.82 96.7 0.37 95.7 0.53
30 min 90.3 0.56 90.7 0.56 96.3 0.86 94.5 0.68
60 min 87.3 0.92 89.9 0.51 96.4 0.49 94.4 0.88
120 min 76.5 0.82 86.1 0.73 96.2 0.72 93.9 0.88
420 min 84.9 2.54 84.2 1.16 94 0.89 92.6 0.34
600 min 93.4 0.82 94.7 0.41     
780 min 94.6 0.49       
* Content = % of drug weighed.
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the carrier will be dissolved, which may cause the dispersion of
composite agglomerates. Our results furthermore show that
changes in the apparent solubility of the drugs and film
formation may introduce additional sources of bias. With the
Figure 3.  Representative SEM images of the salmeterol blend containing a coarse carrier at different mixing times.  Mixing
times are given in minutes. Magnifications on the right hand side are taken from the images on the left hand side.
doi: 10.1371/journal.pone.0069263.g003
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Figure 4.  Representative SEM images of the salmeterol blend containing a fine carrier at different mixing times.  Mixing
times are given in minutes. Magnifications on the right hand side are taken from the images on the left hand side.
doi: 10.1371/journal.pone.0069263.g004
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mixing conditions applied in this study this is especially true for
mixing durations longer than 1 hour. Therefore, the data from
such wet laser diffraction methods have to be interpreted with
good knowledge of all the processes involved and cannot be
Figure 5.  Representative SEM images of the fluticasone blend containing a coarse carrier at different mixing times.  Mixing
times are given in minutes. Magnifications on the right hand side are taken from the images on the left hand side.
doi: 10.1371/journal.pone.0069263.g005
Mixing Time Effects on Powders for Inhalation
PLOS ONE | www.plosone.org 10 July 2013 | Volume 8 | Issue 7 | e69263
Figure 6.  Representative SEM images of the fluticasone blend containing a fine carrier at different mixing times.  Mixing
times are given in minutes. Magnifications on the right hand side are taken from the images on the left hand side.
doi: 10.1371/journal.pone.0069263.g006
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Figure 7.  X50 from laser diffraction analysis of suspended drug particles after dissolution of the carrier material.  Y-error
bars represent minimum and maximum values measured (n = 2).
doi: 10.1371/journal.pone.0069263.g007
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used unconditionally as a measure for the size of detachable
drug agglomerates. To aid in their correct interpretation,
supporting data from other characterisation techniques should
preferably be provided.
Press-on effects
The increase in apparent solubility of salmeterol (Figure 8)
can be explained by the mechanical stress that is imparted on
the drug particles during mixing. This causes disordering or
amorphisation of the initially crystalline particle surface [25,26].
Mixing with the coarse carrier results in a faster increase in
apparent solubility than does mixing with the fine carrier.
Apparently, the higher mass of the coarse carrier particles
results in increased mechanical stress on the drug particles
during collisions and this leads to faster amorphisation. Within
60 minutes of mixing a plateau is reached in the apparent
solubility which is roughly 1.5 times the supposed equilibrium
solubility of the starting material. This means that a maximum
degree of disordering of the salmeterol particles is reached
within this time or that the suspension concentration chosen in
these experiments is not optimal for distinguishing further
disordering [26].
The fact that the drug particles are subjected to significant
mechanical stress during mixing does not only become clear
from the increase in apparent solubility of salmeterol. SEM
imaging of the blends reveals a change in morphology of the
individual drug particles upon prolonged mixing too. This is
most clearly illustrated in Figure 10, where the starting material
is compared with agglomerates found in the mixture with a fine
carrier after 420 (salmeterol) or 780 minutes (fluticasone) of
mixing. Similar agglomerates and similarly shaped primary
particles were not observed in the placebo blends. Therefore,
the agglomerates shown in Figure 10 are likely to consist
primarily of the drug component. The original plate-like
salmeterol particles are extensively plastically deformed,
whereas fluticasone appears to be fragmented into small
needle shaped particles. In the mixture with the coarse carrier,
plate-like salmeterol particles have mostly been deformed to
spherical particles already after 60 minutes of mixing (Figure 3,
B2). When mixed with the fine carrier, the original plate-like
shape of the salmeterol particles is still recognisable after 60
minutes of mixing (Figure 4, B2). Only after 420 minutes of
mixing their original shape is completely lost (Figure 4, C2).
Therefore, the conclusion from the apparent solubility data that
greater mechanical stress is caused by the coarser carrier is in
agreement with the SEM images. Apparently, the larger carrier
surface irregularities of the coarser carrier particles do not offer
sufficient protection to the drug particles from mechanical
stress to balance the higher frictional and inertial forces that
result from a higher mass of this carrier.
The introduction of a higher degree of solid-state disorder
with prolonged mixing may affect the chemical stability of the
formulation. In addition, recrystallisation at the drug-carrier
interface during storage may severely affect the powder’s
dispersion behaviour in a negative way. The inertial and
frictional mixing forces that cause an increase in apparent
solubility may partly act as press-on forces, which cause
increased drug-carrier interactions and thus negatively
influence drug detachment during inhalation. Based on the
faster increase in apparent solubility (Figure 8) a greater
Figure 8.  Change in apparent solubility of salmeterol during mixing with the coarse and fine lactose carrier.  The apparent
solubility is represented by the absorption of the solution at 280 nm.
doi: 10.1371/journal.pone.0069263.g008
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negative contribution from press-on forces to the overall effect
of mixing time on drug detachment may be expected for the
coarse carrier than for the fine carrier.
Drug (re-)distribution
Drug particles are primarily located in carrier surface
irregularities after 0.5 minutes of mixing (Figures 3-6, A1 and
A2). The presented data indicate that the drug particles are
subsequently redistributed over the complete carrier surface
during prolonged mixing, where they may become immobilised
by compression on the carrier surface to form continuous,
coherent films. In addition, certainly for salmeterol, a
substantial fraction of the drug forms large agglomerates
(whether preceded by drug redistribution into carrier surface
irregularities or not). Agglomeration and compression (as a
result of mechanical stress that concurrently causes the film
formation and increased solubility) of the drug particles are
especially pronounced after mixing for at least 60 minutes.
Therefore, after such long mixing times, the redistribution of
drug particles between carrier surface sites with a different
Figure 9.  Light microscopic images of suspended fluticasone films after dissolution of the lactose carrier.  Top: 1.48%
fluticasone mixed with the fine carrier for 600 minutes, the scale bar represents 60 µm; bottom: 0.4% fluticasone mixed with the
coarse carrier for 420 minutes, the scale bar represents 15 µm.
doi: 10.1371/journal.pone.0069263.g009
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intrinsic binding activity is likely to be of minor importance than
press-on and agglomeration effects to the overall effect of
mixing time on drug detachment. With shorter mixing
distribution effects may be more significant.
Drug detachment
The data presented in Figure 11 confirm that the effect of
mixing time on drug detachment is dependent on the type of
drug, the carrier size fraction and the flow rate. The effect of
mixing time is most pronounced within the first 120 minutes of
mixing.
For salmeterol mixed with the coarse carrier, drug
detachment at a flow rate of 20 L/min increases from 23.9%
after 2 minutes of mixing to 43.4% after 420 minutes of mixing.
These values are in line with the change in the amount of drug
that is contained in easily detachable agglomerates, as was
measured with the segregation sensitivity test (i.e. 15.6% to
52.4%, respectively). Therefore, the positive effect may be the
result of a dominance of agglomerate formation. However, the
maximum increase in drug detachment is already attained
within the first 30 minutes of mixing, whereas agglomeration
seemed to occur mostly from 10 to 420 minutes of mixing
(based on the laser diffraction data in Figure 7) or from 60–420
minutes of mixing (based on the SEM images in Figure 3).
Therefore, other effects may have contributed to the positive
effect as well. The observed change in the shape of the
salmeterol particles by SEM could be one of those additional
effects (as shown in Figure 3, B2). At 60 L/min, the effect of
mixing time is dominated by press-on effects and possibly
some migration of drug particles towards active binding sites
(distribution effects). In the first 10 minutes of mixing
deagglomeration may also contribute to a lower drug
detachment (i.e. a lower ratio of inertial separation to binding
force due to a lower drug agglomerate mass). As a result, drug
detachment decreases from nearly 100% after 0.5 minutes of
mixing to 75% after 120 minutes of mixing and an opposite
effect from that at 20 L/min is thus obtained. In other words, not
Figure 10.  Representative SEM images showing morphological changes to the drug particles occurring during
mixing.  Top: the salmeterol (SX) and fluticasone (FP) starting materials; bottom: drug agglomerates on the fine carrier after a
certain mixing time (in minutes).
doi: 10.1371/journal.pone.0069263.g010
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the whole drug particle mass is affected by mixing time in the
same way. The salmeterol fraction that is contained in easily
detachable agglomerates increases (Figure 11: coarse, 20 L/
min) concurrently with the fraction that is contained in a
strongly bound film on the carrier surface (Figure 11: coarse,
60 L/min). Which effect is measured depends on the dispersion
efficacy (i.e. flow rate) during the drug detachment
experiments. The fact that, at 60 L/min, a plateau in drug
detachment is reached suggests that during mixing a dynamic
equilibrium is established between drug that is present in the
strongly bound film on the carrier surface and drug that is
present as more readily detachable drug particles (including
agglomerates).
In contrast to the coarse carrier, prolonged mixing with the
fine carrier results in a negative effect on drug detachment at
20 L/min. Because the agglomeration of salmeterol is less
pronounced with the finer carrier, the positive contribution from
this effect is not dominant over any negative contribution from
increased compression of the drug onto the carrier surface and
redistribution of drug towards active binding sites. The greater
dominance of press-on and possibly distribution effects is also
apparent at 60 L/min, because no plateau value is reached and
the minimum amount of drug detached is lower than with the
coarse carrier (42% versus 75%, respectively). Based on the
SEM images and apparent solubility data it was concluded that
mechanical stress and thus press-on forces on the drug
particles are lower for the fine carrier. This effect, which should
result in improved drug detachment, is apparently offset by the
decrease in agglomeration from the coarse to the fine carrier.
For fluticasone, drug detachment at 20 L/min stays relatively
constant on continued mixing with the coarse carrier. This
suggests that effects from agglomeration are balanced by
press-on effects and distribution effects and are thus less
dominant than is the case for salmeterol. This is in agreement
with the lower degree of agglomeration that was observed for
fluticasone. Also the lower plateau value in drug detachment
that is reached at 60 L/min indicates that the dynamic
equilibrium between drug being present as detachable
agglomerates and as strongly adhering films is shifted towards
the latter when changing salmeterol for fluticasone. The effect
of mixing time is comparable for both drugs when mixed with
the fine carrier. This too is in agreement with the less
pronounced difference in their agglomeration behaviour (which
Figure 11.  Drug detachment at 20 and 60 L/min as function of mixing time.  Y-error bars represent minimum and maximum
values measured (n = 5).
doi: 10.1371/journal.pone.0069263.g011
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for salmeterol is likely restricted by the smaller surface
irregularities).
Practical implications
The results show that the mixing time should be carefully
considered for the formulation of carrier-based inhalation
powders. The optimal mixing time may vary depending on the
formulation purpose and the choice for other, interacting
variables. A balance between satisfactory homogeneity and
mechanical stability on the one hand and dispersibility on the
other may be achieved at relatively short mixing times.
However, the effect of mixing time is also most pronounced at
the start of mixing, and therefore, a sufficiently robust process
may require longer mixing instead. For research purposes it
may be desirable to stress press-on effects or agglomeration
effects, which can be achieved by prolonged mixing, especially
when using a coarse carrier fraction.
The need for a careful consideration of the applied mixing
time is further stressed by the fact that the relevance of mixing
time is not restricted to the homogeneity and dispersion
performance of the powder formulation. The mechanical stress
from (prolonged) mixing may influence the solid state of the
drug and, with that, its dissolution behaviour (absorption) after
inhalation and subsequent deposition in the lungs and the
physical and chemical stability of the mixture during storage.
The long mixing times that have been applied in this study
may not be representative for the mixing times applied in
industrial dry powder inhalation formulation. However, many of
the effects that are shown in is this paper may occur at a higher
rate when larger batch sizes and higher shear mixing principles
are used, as is common for industrial processes. For example,
it was shown that 1 hour of mixing with the low shear Turbula
blender used in this study (operated at 90 rpm) results in a
similar dispersion performance as 5 minutes of mixing with a
lab-scale high shear blender (i.e. Picomix operated at 1000
rpm) [27].
Future perspectives
The overall effect of mixing time on drug detachment is likely
to depend on more variables than the ones addressed in this
paper. Examples are the dispersion principle, the drug content,
the carrier surface roughness, the mixing principle and the
mixing intensity. Furthermore, the change in drug detachment
is only an indication of the change in the maximum fine particle
fraction that can be obtained, depending on the degree of
agglomerate dispersion following detachment. Therefore, much
is still to be learned from future investigations that address
these factors in combination with the right techniques to
measure or monitor the relevant powder properties.
Conclusions
Quantitative and qualitative interactions occur between the
effect of mixing time on drug detachment and the type of drug,
the carrier size fraction and the flow rate used. This can be
satisfactorily explained with a balance of three processes which
take place during mixing, i.e., drug (de-) agglomeration,
compression onto and (re-)distribution over the carrier surface.
A combination of SEM, laser diffraction techniques and the
measurement of the apparent solubility of the drug can be used
to qualitatively analyse these processes, but an exact
quantification requires further improvement of these or the
development of other techniques.
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